257 related articles for article (PubMed ID: 17229513)
1. The effect of withholding gonadotropin (a coasting period) on the outcome of in vitro fertilization cycles.
Owj M; Tehrani Nejad ESh; Amirchaghmaghi E; Ezabadi Z; Baghestani AR
Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):81-5. PubMed ID: 17229513
[TBL] [Abstract][Full Text] [Related]
2. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
3. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome.
Delvigne A; Kostyla K; Murillo D; Van Hoeck J; Rozenberg S
Int J Fertil Womens Med; 2003; 48(1):25-31. PubMed ID: 12643517
[TBL] [Abstract][Full Text] [Related]
4. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
[TBL] [Abstract][Full Text] [Related]
5. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
6. Effect of coasting on IVF cycle characteristics and outcome in short vs. long GnRH agonist protocols.
Farhi J; Fisch B; Sapir O; Pinkas H; Ben-Haroush A
Gynecol Endocrinol; 2010 Mar; 26(3):187-92. PubMed ID: 20148740
[TBL] [Abstract][Full Text] [Related]
7. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
Kumbak B; Kahraman S
Acta Obstet Gynecol Scand; 2009; 88(5):563-8. PubMed ID: 19306135
[TBL] [Abstract][Full Text] [Related]
9. [Oocyte and embryo quality and outcome of ICSI cycles in patients with polycystic ovary syndrome (PCOS) versus normo-ovulatory].
Kdous M; Chaker A; Zhioua A; Zhioua F
J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):133-43. PubMed ID: 19179017
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
[TBL] [Abstract][Full Text] [Related]
11. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
[TBL] [Abstract][Full Text] [Related]
12. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
13. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
[TBL] [Abstract][Full Text] [Related]
14. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients.
Michaan N; Ben-David G; Ben-Yosef D; Almog B; Many A; Pauzner D; Lessing JB; Amit A; Azem F
Eur J Obstet Gynecol Reprod Biol; 2010 Apr; 149(2):175-7. PubMed ID: 20074845
[TBL] [Abstract][Full Text] [Related]
15. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
[TBL] [Abstract][Full Text] [Related]
16. Falling FSH levels predict poor IVF pregnancy rates in patients whom the gonadotropins are withheld.
Erman Akar M; Oktay K
Arch Gynecol Obstet; 2009 Nov; 280(5):761-5. PubMed ID: 19255769
[TBL] [Abstract][Full Text] [Related]
17. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.
Mansour R; Aboulghar M; Serour G; Amin Y; Abou-Setta AM
Hum Reprod; 2005 Nov; 20(11):3167-72. PubMed ID: 16006465
[TBL] [Abstract][Full Text] [Related]
18. Does coasting, a procedure to avoid ovarian hyperstimulation syndrome, affect assisted reproduction cycle outcome?
Yilmaz N; Uygur D; Ozgu E; Batioglu S
Fertil Steril; 2010 Jun; 94(1):189-93. PubMed ID: 19376515
[TBL] [Abstract][Full Text] [Related]
19. The role of ketoconazole in the prevention of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during assisted reproductive technology cycles.
Owj M; Tehrani-Nejad ES; Amirchaghmaghi E; Baghestani AR; Ahmadi J
Saudi Med J; 2005 Oct; 26(10):1584-7. PubMed ID: 16228060
[TBL] [Abstract][Full Text] [Related]
20. Coasting. A viable option for patients at risk of ovarian hyperstimulation syndrome.
Gafar AH; Abotalib ZM
Saudi Med J; 2002 Nov; 23(11):1398-401. PubMed ID: 12506304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
